ArticleAnnals of hematology2026
Identification of genetic variants in the FGB gene associated with congenital hypofibrinogenemia with divergent clinical phenotype.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congenital fibrinogen disorders are rare and clinically heterogeneous conditions that may manifest with both bleeding and thrombotic complications. The relationship between genotype and phenotype remains incompletely understood, particularly in cases involving co-inherited variants with potentially opposing functional effects. We investigated two families with hypofibrinogenemia using coagulation assays, rotational thromboelastometry (ROTEM), genetic analysis, and protein modelling. In the first family, an 18-year-old patient with mild bleeding carried two heterozygous FGB variants: c.794 C > T (p.Pro265Leu) and c.1102T > C (p.Tyr368His), and showed reduced clot firmness on ROTEM, consistent with a quantitative fibrinogen defect. Segregation analysis indicated that p.Pro265Leu was associated with decreased fibrinogen levels, whereas p.Tyr368His was present in an asymptomatic relative. In the second family, an 11-year-old patient and her father carrying p.Tyr368His presented with asymptomatic hypofibrinogenemia and relatively preserved ROTEM parameters, suggesting a limited impact of this variant on fibrin-based clot formation. Protein modelling indicated that p.Tyr368His had the more pronounced predicted structural effect, showing moderate local destabilization in both isolated and assembled models, whereas p.Pro265Leu showed a mild and context-dependent effect that was largely compensated in the trimeric fibrinogen structure. These findings demonstrate that co-inherited fibrinogen variants may exert distinct and potentially opposing effects on clot formation, contributing to variable clinical phenotypes. Integration of genetic data with global functional assays such as ROTEM and with structural modelling provides important insights into variant-specific effects and may improve the interpretation of pathogenicity and support individualized clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.